


# PRODUCT INFORMATION



## Erteberel

Item No. 22130

**CAS Registry No.:** 533884-09-2  
**Formal Name:** (3aS,4R,9bR)-1,2,3,3a,4,9b-hexahydro-4-(4-hydroxyphenyl)-cyclopenta[c][1]benzopyran-8-ol  
**Synonym:** LY500307  
**MF:** C<sub>18</sub>H<sub>18</sub>O<sub>3</sub>  
**FW:** 282.3  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 225 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Erteberel is supplied as a crystalline solid. A stock solution may be made by dissolving the erteberel in the solvent of choice, which should be purged with an inert gas. Erteberel is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of erteberel in these solvents is approximately 30 mg/ml.

### Description

Erteberel is an estrogen receptor beta (ERβ) agonist.<sup>1</sup> It is selective for ERβ over ERα in reporter assays using PC3 cells expressing the human receptors (EC<sub>50</sub>s = 0.66 and 19.4 nM, respectively). Erteberel (5 μM) induces apoptosis and cell cycle arrest at the G<sub>2</sub>/M phase in U87MG and U251 glioblastoma cells.<sup>2</sup> It enhances cytotoxicity induced by cisplatin (Item No. 13119), lomustine (Item No. 21237), or bleomycin (Item No. 13877) in U251 cells when used at a concentration of 1 μM. Erteberel (5 mg/kg) reduces tumor growth in a U251 orthotopic model of glioblastoma in ovariectomized mice. It decreases prostate weight but does not affect serum testosterone or dihydrotestosterone levels in a mouse model of benign prostatic hyperplasia (BPH) when administered at doses of 0.01, 0.025, and 0.05 mg/kg.<sup>1</sup>

### References

1. Thomas, K.A., Rios-Candelore, M., Giménez-Gallego, G., *et al.* Pure brain-derived acidic fibroblast growth factor is a potent angiogenic vascular endothelial cell mitogen with sequence homology to interleukin 1. *Proc. Natl. Acad. Sci. USA* **82(19)**, 6409-6413 (1985).
2. Sareddy, G.R., Li, X., Liu, J., *et al.* Selective estrogen receptor β agonist LY500307 as a novel therapeutic agent for glioblastoma. *Sci. Rep.* **6:24185**, (2016).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/26/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM